Global Fondaparinux Market Size, Share & Trends Analysis Report, By Product Type (Branded and Generics) and Forecast, 2020-2026
The global fondaparinux market is estimated to grow significantly during the forecast period. The major factors contributing to the market growth include a significant rise in the prevalence of deep vein thrombosis (DVT) and rising geriatric population. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age of 65, increased from 1 in 11 in 2019. In 2019, 703 million people were aged 65 years or over globally, which is expected to double to 1.5 billion in 2050. Increasing geriatric population is one of the major causes for an increase prevalence of osteoporosis, which results in the emerging demand for hip and knee replacement procedures. This contributes to the rising adoption of fondaparinux to prevent venous thromboembolic events (VTE) in patients who are undergoing orthopedic surgeries of the lower limbs including hip replacement surgery, hip fracture, and knee surgery. Fondaparinux works by blocking the activity of some clotting substances in the blood. It is being significantly used owing to the longer half-life and high efficiency than heparin.
Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is expected to hold a significant share in the market owing to the rising number of hip and knee replacement procedures in the region. In 2015, 57,673 hip primary replacement were performed by 2,572 surgeons in the US and 87,593 primary knee replacement procedures were performed by 2,281 surgeons in the country. These procedures are rising significantly owing to the rising prevalence of orthopedic conditions in the country, which in turn, contributes to the adoption of fondaparinux to prevent blood clot after the hip and knee replacement procedure.
Some key players in the market include Mylan N.V., GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Inc., Aurobindo Pharma Ltd., and Cadila Healthcare Ltd. (CHL). The strategies adopted by the market player include mergers and acquisitions and product launches to expand market share and gain a competitive advantage. For instance, in December 2017, Aurobindo Pharma Ltd. gained the US FDA approval for production and marketing of its generic version of Fondaparinux sodium injection, 2.5mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL single-dose prefilled syringes, for the prevention of DVT. The approved ANDA is a therapeutically equivalent and bioequivalent to the reference listed drug (RLD) product Arixtra Injection of Mylan Ireland. The product was introduced in January 2018.
Research Methodology
The market study of the global fondaparinux market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Global Fondaparinux Market Research and Analysis by Product Type
The Report Covers
The global fondaparinux market is estimated to grow significantly during the forecast period. The major factors contributing to the market growth include a significant rise in the prevalence of deep vein thrombosis (DVT) and rising geriatric population. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age of 65, increased from 1 in 11 in 2019. In 2019, 703 million people were aged 65 years or over globally, which is expected to double to 1.5 billion in 2050. Increasing geriatric population is one of the major causes for an increase prevalence of osteoporosis, which results in the emerging demand for hip and knee replacement procedures. This contributes to the rising adoption of fondaparinux to prevent venous thromboembolic events (VTE) in patients who are undergoing orthopedic surgeries of the lower limbs including hip replacement surgery, hip fracture, and knee surgery. Fondaparinux works by blocking the activity of some clotting substances in the blood. It is being significantly used owing to the longer half-life and high efficiency than heparin.
Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is expected to hold a significant share in the market owing to the rising number of hip and knee replacement procedures in the region. In 2015, 57,673 hip primary replacement were performed by 2,572 surgeons in the US and 87,593 primary knee replacement procedures were performed by 2,281 surgeons in the country. These procedures are rising significantly owing to the rising prevalence of orthopedic conditions in the country, which in turn, contributes to the adoption of fondaparinux to prevent blood clot after the hip and knee replacement procedure.
Some key players in the market include Mylan N.V., GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Inc., Aurobindo Pharma Ltd., and Cadila Healthcare Ltd. (CHL). The strategies adopted by the market player include mergers and acquisitions and product launches to expand market share and gain a competitive advantage. For instance, in December 2017, Aurobindo Pharma Ltd. gained the US FDA approval for production and marketing of its generic version of Fondaparinux sodium injection, 2.5mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL single-dose prefilled syringes, for the prevention of DVT. The approved ANDA is a therapeutically equivalent and bioequivalent to the reference listed drug (RLD) product Arixtra Injection of Mylan Ireland. The product was introduced in January 2018.
Research Methodology
The market study of the global fondaparinux market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Global Fondaparinux Market Research and Analysis by Product Type
The Report Covers
- Comprehensive research methodology of the global fondaparinux market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global fondaparinux market.
- Insights about market determinants, which are stimulating the global fondaparinux market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Apicore LLC
- Aurobindo Pharma Ltd.
- Cadila Healthcare Ltd. (CHL)
- Dr Reddy’s Laboratories Ltd.
- GlaxoSmithKline plc
- Italfarmaco S.p.A.
- Mylan N.V.
- Sandoz International GmbH
- ScinoPharm Taiwan, Ltd.
